Key Highlights
● Dr. Anil R. Diwan will continue as President until June 30, 2027 at a base annual salary of $400,000.
● Dr. Diwan also receives 10,204 Series A Preferred shares, vesting quarterly from September 30, 2026 through June 30, 2027.
● CFO Meeta Vyas's one-year extension runs from July 1, 2026 through June 30, 2027 at $10,800 per month.
● Both agreements were signed on September 25, 2026 but are effective July 1, 2026, which the filing does not explain.
NanoViricides, Inc. (NYSE:NNVC) filed a Form 8-K on September 29, 2026 reporting that it signed extension agreements on September 25, 2026 with two senior officers: President Dr. Anil R. Diwan and Chief Financial Officer Meeta Vyas. Both extensions cover the period from July 1, 2026 through June 30, 2027. The filing reports them under Item 5.02, which covers compensatory arrangements with certain officers, and attaches the agreements as Exhibits 10.1 and 10.2.
Dr. Diwan's Extension
The 8-K says the extension with Dr. Diwan is effective July 1, 2026 and builds on his original employment agreement dated July 1, 2018. It states: "The Extension provides that Dr. Diwan will continue to serve as the Registrant's President until June 30, 2027 at a base annual base salary of $400,000."
In addition to salary, the filing says Dr. Diwan will receive a grant of 10,204 shares of the company's Series A Preferred Stock, par value $0.00001 per share. The shares vest in quarterly installments beginning September 30, 2026, and are fully vested by June 30, 2027.
The filing also describes other terms. Dr. Diwan participates in employee fringe benefits and senior executive benefits, and the agreement includes a term life insurance policy valued at $2 million, of which $1 million is for the company and $1 million for his estate. If he were terminated without cause, the filing says he would be eligible for six months of salary, payable as a lump sum or in installments, with continued benefits.
Ms. Vyas's Extension
The extension with Ms. Vyas is also effective July 1, 2026 and runs for one year through June 30, 2027. The filing describes it as being under the same general terms as her original agreement, which is dated May 31, 2013. In the filing's words, "The Vyas Extension is for a period of one year from July 1, 2026 through June 30, 2027 under the same general terms." The filing notes that her arrangement is renewable annually.
Her compensation is stated as $10,800 per month. The filing says that figure was increased from $9,000 in January 2015. It also describes a benefit under which she receives reimbursement of up to 50 percent of medical, dental and Medicare costs, to a maximum of $2,500 per month.
Timing and Context
Both agreements are effective from July 1, 2026, but the 8-K reports that they were signed on September 25, 2026. The extensions therefore cover a period that had already begun when they were signed, and the filing does not explain that timing. The report date on the cover page is September 28, 2026, and the filing was submitted on September 29, 2026. Dr. Diwan signed the 8-K as the company's President and Chairman.
The filing contains no information about approval by the board of directors or its compensation committee. The company is a Delaware corporation with its address in Shelton, Connecticut, and its common stock trades under the symbol NNVC.
Item 5.02 requires a company to disclose material compensatory arrangements with its named executive officers. The 8-K therefore describes the terms in summary form and refers readers to the exhibits for the full agreements.
NanoViricides Extensions Run to June 30, 2027
The key date is June 30, 2027, when both extensions end. The filing describes Ms. Vyas's arrangement as renewable annually. The vesting of Dr. The 8-K itself gives no dollar value for the preferred stock grant. Diwan's Series A Preferred shares runs quarterly from September 30, 2026 through June 30, 2027.






Please wait processing your request...